ADC

Asia leads in bispecific ADCs

Bispecific antibody drug conjugates represent a new and promising development in targeted cancer therapy. The technology combines the precision of monoclonal antibodies with...

Bioteknik

Kina

Premium

Targinta CEO: "Strong interest in ADCs in 2023"

In 2023, we have seen several significant deals...

Intervju

BioInvent reaches research milestone in collaboration with Exelixis

BioInvent has reached a research milestone in its collaboration...

Intervju

Targinta positions itself within the ADC field

The field of Antibody-Drug Conjugates has grown rapidly in recent years...

Intervju

BioStock Studio: Targinta on the next steps

An exciting year awaits oncology company Targinta, where...

Intervju

Video

Xintela's cancer project awarded two million SEK by Vinnova

Lund company Xintela ended last week on a positive note...

Xintela's collaboration with the orthopedics giant may be expanded

Cell therapy and oncology company Xintela is in a...

Xintela: »Interest in cell therapy is very high in Asia«

With a busy 2018 in the rearview mirror, Xintela has...

Genovis launches product with an eye on the expansive antibody market

Genovis finished last year strong with a sales increase...

Genovis enters 2017 with several trump cards in hand

Merck, Roche, Genentech, Johnson&Johnson and Pfizer are not at the top...